Objective: Adiponectin signalling attenuates insulin resistance (IR) and steatosis hepatis in animal models. As adiponectin receptor (ADIPOR)1 and ADIPOR2 are critical components in the adiponectin signalling cascade, we studied hepatic ADIPOR1/2 mRNA levels in humans and their relation to IR. Design: We determined metabolic risk factors and levels of hepatic mRNA transcribed from ADIPOR1, ADIPOR2 and FOXO1, a putative up-stream regulator, in 43 and 34 obese subjects with low and high homeostasis model assessment-IR, respectively. Results: Plasma adiponectin and metabolic risk factors showed associations with IR as expected. Both hepatic ADIPOR1 and ADIPOR2 mRNA expression levels were higher in insulin-resistant subjects (Po0.0035). ADIPOR1 mRNA correlated with FOXO1 mRNA in obese insulin resistant (P ¼ 0.0034), but not insulin-sensitive subjects, while no correlations of ADIPOR2 with FOXO1 mRNA were noted. FOXO1 enhanced transcription from the ADIPOR1, but not the ADIPOR2 promoter in HepG2 cells. Conclusion: Increased hepatic ADIPOR1 and ADIPOR2 mRNA in insulin-resistant obese subjects may, at least in part, reflect a compensatory mechanism for reduced plasma adiponectin. FOXO1 may contribute to enhanced ADIPOR1, but not ADIPOR2 transcription in IR.
Insulin resistance (IR), a hallmark of type 2 diabetes, is associated with enhanced cardiovascular risk 1,2 as well as non-alcoholic fatty liver disease. 3 Studies in lipodystrophic and obese humans as well as in animal models suggest that adipose tissue (AT) has an important role in IR. [4] [5] [6] Expansion of AT is associated with pro-inflammatory changes and altered adipokine secretion, thereby affecting the function of distant tissues such as skeletal muscle, liver and vascular cells. [7] [8] [9] However, clinical experience and well-documented studies in different populations indicate that metabolically benign, insulin-sensitive phenotypes are not infrequent within the obesity spectrum. 10, 11 Adiponectin is the most abundant adipokine in the circulation and has insulin-sensitizing, anti-inflammatory and atheroprotective properties. 12 Associations of low plasma adiponectin levels with IR, components of the metabolic syndrome, the incidence of type 2 diabetes and increased cardiovascular risk, independent of established risk factors, have been shown repeatedly. 12, 13 Adipocytes secrete adiponectin as a low-molecular weight trimer, a middlemolecular weight hexamer or a high-molecular weight 12-to 18-mer into the circulation. [14] [15] [16] Two adiponectin receptors have been identified that mediate biological effects of adiponectin forms. In mice, adiponectin receptor AdipoR1 is ubiquitously expressed, whereas AdipoR2 is mostly expressed in liver. 16 Interestingly, mice with targeted disruption of both AdipoR1 and AdipoR2 appeared to be more glucose intolerant and insulin resistant than adiponectin-knockout mice, a finding that suggests AdipoR1/2 effects extend beyond the role of adiponectin itself. 17 A major target of adiponectin signalling is the liver, in which adiponectin increases glucose utilization, fatty acid oxidation and the inhibitory effect of insulin on hepatic gluconeogenesis. 18, 19 In mouse liver, changes in plasma insulin induced by fasting and refeeding were inversely associated with AdipoR1/2 transcript levels. 20 As the relation of hepatic ADIPOR1/2 mRNA levels with IR has not been studied in humans, we determined adiponectin plasma levels and ADIPOR1/2 transcript levels in insulin-sensitive and insulin-resistant obese subjects.
Materials and methods

Study population
The study included 43 insulin-sensitive and 34 insulinresistant patients. Obese subjects were selected from a group of 4200 patients, who underwent a surgical weight reducing procedure. Selection criteria for insulin-sensitive and insulin-resistant subjects included fasting blood glucose o6.11 mmol l -1 , no history of diabetes or use of glucose or lipid lowering medication, C-reactive protein levels o30 mg l -1 (to exclude patients with major acute or chronic inflammatory diseases), no weight changes 43% during the last 2 months and homeostasis model assessment (HOMA) IR o2.5 or 45 for insulin-sensitive or insulin-resistant subjects, respectively. All study subjects provided informed consent and study protocols were approved by the local ethics committee. AT mass was determined by bioelectric impedance analysis using the phase-sensitive, multifrequence analyzer BIA-2000 M (Data input, Hofheim, Germany). Abdominal subcutaneous AT and visceral AT diameters were determined by ultrasonography. 21 Grading of fatty liver disease was determined by ultrasound. 22 Level 0 was defined as a normal echo pattern of the liver (as compared with kidney), level 1 as a slight increase in the echo pattern with normal visualization of the diaphragm and vessels, level 2 as a moderately increased echogenic pattern with reduced visibility of vessels and diaphragm and level 3 as a pronounced increase in hepatic echogenicity with poor visibility of intrahepatic vessels and posterior right lobe of the liver. We evaluated the grading procedure in 53 patients, in whom liver biopsies were graded for fat content by histology, and observed a strong correlation between the methods (Spearman's R ¼ 0.7733, Po0.0001). Tissue biopsies, obtained from liver during surgery, were collected in RNA-later (Ambion, Austin, TX, USA).
Laboratory analyses
Plasma glucose, insulin, cholesterol, triglycerides, highdensity lipoprotein cholesterol, apolipoprotein AI and apolipoprotein B and C-reactive protein were determined as described. 23 Plasma ferritin was measured using Ferritin ElektroChemiLumineszenz ImmunoAssay 'ECLIA' kit and the modular analytics E179 from Roche (Basel, Switzerland). Plasma adiponectin was measured using the Human Adiponectin/Acrp30 immunoassay (R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany). Intra-and inter-assay coefficient of variations (CVs) of immunoassays were o8%. Total RNA was isolated from liver using the RNeasy Mini Kit (QIAGEN, Hilden, Germany). RNA samples were digested with DNase I (Promega, Mannheim, Germany) to eliminate any contaminating DNA. Equal amounts of RNA were reverse transcribed.
24 ADIPOR1 (Hs00360422_m1), ADIPOR2
(Hs00226105_m1) and mRNA levels of the gene encoding forkhead box 01A (FOXO1; Hs00231106_ml) were quantified in duplicate using TaqMan gene expression assays (Applied Biosystems, Warrington, UK) listed in parentheses and the iCycler iQ Multicolour Real-Time PCR Detector (Bio-Rad, Hercules, CA, USA). Constitutively expressed acidic ribosomal protein p0 (ARP0) mRNA was measured for normalization of mRNA abundance as described. 25 The average inter-assay CV of mRNA measurements ascertained by overlapping complementary DNA samples was 12%. Data are presented as average ratios of target mRNA to ARP0 (s.d.) in liver in arbitrary units. The ADIPOR1-Prom-Luc construct containing a 3350-bp fragment of the human ADIPOR1 promoter was generated using 5 0 -GAGAGGTACCCCCAGCTGCCCCTCA CAGTGTTCCCT-3 0 (À3268 to À3243) and 5 0 -GAGACTC GAGTTCAGCGCCCTCCCCGCGCCGGAAGG-3 0 ( þ 58 to þ 83) as forward and reverse primers, containing KpnI and XhoI sites (underlined), respectively. The PCR amplified DNA fragment was cloned into the pGL4.11 vector (Promega). Numbers in parentheses refer to primer positions relative to the transcriptional start site (GenBank accession no. NM_015999.3). The ADIPOR2-Prom-Luc construct containing a 3494-bp fragment of the human ADIPOR2 promoter was generated using 5 0 -GAGAGGTACCCAGAGGGACT GATGTGACGACATT-3 0 (À3493 to À3469) and 5 0 -GA GACTCGAGATGCCGCTTCTGGAATCGCGCTCTCG-3 0 (À27 to þ 1) as forward and reverse primers, containing KpnI and XhoI sites (underlined), respectively. The PCR amplified DNA fragment was cloned into KpnI and XhoI digested pGL4.11 vector (Promega). Numbers in parentheses refer to primer positions relative to the transcriptional start site (GenBank accession no. NM_024551.2). FOXO1 expression plasmid was a kind gift of Frederic G Barr, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. The mammalian expression vector containing the human complementary DNA for peroxisome proliferator-activated receptor gamma coactivator-1a (PGC-1a) driven by the cytomegalovirus immediate-early promoter (hPGC-1a) has been described. 26 Human HepG2 hepatoma cells were grown as recommended by the supplier (ATCC, Manassas, VA, USA). For transient expression reporter assays, HepG2 cells were cultured in 24-well dishes and transfected using LipofectAMINE 2000 reagent as described. 23 We used 200 ng of reporter plasmids, 250 ng of expression plasmids and 20 ng of pGL4.74(hRluc/TK) (Promega) as transfection control per well. Cells were collected 24 h after transfection and firefly and renilla luciferase activities were measured in a Centro LB 960 luminometer (Berthold Technologies, Bad Wildbad, Germany) using the dual-luciferase reporter assay system (Promega). 
Statistical analyses
Results
As expected from the selection criteria, average values for HOMA-IR, plasma glucose and insulin were higher in obese subjects with high HOMA-IR in comparison with obese subjects with low HOMA-IR (Table 1 ). The proportion of men to women was significantly greater in the high HOMA-IR group. Compared with obese subjects with low HOMA-IR, obese, high HOMA-IR patients showed more frequently and/or more advanced hepatic steatosis and greater mean values for visceral AT diameter and plasma triglycerides, while average values for high-density lipoprotein cholesterol and adiponectin were lower. Hepatic ADIPOR1 and ADIPOR2 mRNA expression levels in obese patients with IR were higher than in obese, insulin-sensitive subjects (Table 2) . Sex-specific analysis showed similar differences for hepatic ADIPOR1 (P ¼ 0.0039) and ADIPOR2 mRNA (P ¼ 0.0180) in the larger group of females, whereas no significant differences were observed in men (Supplementary Table 1 ). In women, no associations of hepatic ADIPOR1/2 mRNA levels with menopause or use of contraceptive hormones were observed (data not shown). To ascertain possible confounding by inflammatory disorders, we compared ADIPOR1/2 mRNA levels in subjects with C-reactive protein levelso10 mg l -1 and observed similar differences between the low and high HOMA-IR group as in the entire population (Supplementary Table 2 ). As previous studies showed altered levels of hepatic ADIPOR1/2 mRNA in patients with steatosis and/or non-alcoholic steatohepatitis (NASH), [27] [28] [29] we adjusted the analyses for steatosis grade and plasma ferritin, a marker of hepatic inflammation, but between group differences for ADIPOR1 (P ¼ 0.0020) and ADIPOR2 mRNA (P ¼ 0.0035) were maintained. Previous studies in mice showed that the expression of AdipoR1 and AdipoR2 mRNA is regulated through the phosphoinositide 3-kinase/Foxo1-dependent pathway. 20 To determine, whether this pathway may also have a role in livers of obese humans with IR, we measured FOXO1 mRNA in liver biopsies. FOXO1 mRNA did not differ significantly between groups (14.46 (8.70) and 14.70 (11.87) arbitrary units in the low and the high HOMA-IR groups, respectively). As increased expression and activity of FOXO1 has been associated with NASH 30 and NASH is strongly related to the steatosis score in obese subjects, 31 we determined the relation of hepatic FOXO1 mRNA with steatosis score.
Although average values (s.d.) for FOXO1 mRNA tended to increase from 12.54 (5.19) in the steatosis score group 0 to 14.55 (9.77) in score group 1 and 15.78 in score group 2, sex, age and study group adjusted mRNA levels showed no significant association with steatosis score. However, a correlation between FOXO1 and ADIPOR1 mRNA was observed in the high, but not in the low HOMA-IR group (Table 3) . In neither group were correlations of FOXO1 and ADIPOR2 mRNA observed. To further test possible influences Hepatic ADIPOR1/2 transcripts in insulin resistance TK Felder et al of FOXO1 on ADIPOR1 or ADIPOR2 transcription, we performed transient co-transfection studies in HepG2 cells with a FOXO1 expression plasmid and ADIPOR1-Prom-Luc or ADIPOR2-Prom-Luc, two luciferase reporter constructs under the control of the ADIPOR1 or ADIPOR2 promoters. These studies showed that FOXO1 activated transcription of the ADIPOR1, but not the ADIPOR2 promoter (Figure 1 ). PGC-1a, shown to coactivate FOXO1 at some promoters, 32 had no additional effect on the FOXO1-mediated activation of the ADIPOR1 promoter.
Discussion
In this study, we compared obese subjects with marked differences in insulin sensitivity and confirmed results of many other reports showing lower plasma adiponectin levels in insulin-resistant subjects. As a major finding, we observed increased hepatic ADIPOR1 and ADIPOR2 mRNA levels in association with IR. Recent studies have revealed beneficial effects of adiponectin signalling in many organs including the liver. Specifically, adiponectin signalling alleviated or prevented NASH in mice, 33, 34 and associations of hypoadiponectinaemia with fatty liver and/or NASH have been reported in humans. 35, 36 Furthermore, genetic studies revealed associations of ADIPOR1/2 with IR and liver fat content, 37, 38 and overexpression of ADIPOR1/2 has been shown to potentiate subeffective doses of adiponectin. 39 We therefore suggest that the increased ADIPOR1/2 mRNA expression in obese, insulin-resistant subjects represents a mechanism that may partially compensate for reduced plasma adiponectin. Previous studies in humans reported associations of hepatic ADIPOR1/2 mRNA levels with hepatic steatosis and/or NASH. In obese patients, ADIPOR2 mRNA was lower in 13 patients with varying grades of NASH in comparison with nine patients with simple steatosis, but comparable HOMA-IR. A trend for reduced ADIPOR1 mRNA in NASH was noted as well and immunohistochemical staining in five patients per group revealed a trend for lower ADIPOR2 expression in NASH patients. 27 However, two other studies showed increased hepatic ADIPOR2 mRNA levels in NASH patients with high HOMA-IR in comparison with control subjects with low HOMA-IR. 28, 29 ADIPOR1 mRNA levels, measured in one study, were higher in obese patients with high HOMA-IR and NASH than in non-obese controls with low HOMA-IR. In obese subjects with pure hepatic steatosis, average levels of ADIPOR1/2 mRNA as well as HOMA-IR were intermediate between NASH patients and controls. 29 These contrasting results may be reconciled by an association of ADIPOR1/2 mRNA levels with IR as observed in our study. As NASH is strongly related to the steatosis score in obese subjects as ascertained by ultrasound, 31 our analyses adjusting for steatosis grade and plasma ferritin would be expected to reduce potential confounding by NASH. In contrast to our findings in liver, inverse associations of ADIPOR1 and/or ADIPOR2 mRNA levels with IR have been observed in AT. In omental and subcutaneous ATs, ADIPOR1 mRNA was lower in obese subjects than in controls 40 and ADIPOR1/2 mRNA levels were reduced in visceral and subcutaneous ATs from obese subjects with NASH in Hepatic ADIPOR1/2 transcripts in insulin resistance TK Felder et al comparison with non-obese controls. 29 Euglycaemic-hyperinsulinaemic clamp studies showed that ADIPOR2, but not ADIPOR1 mRNA levels in visceral and subcutaneous AT were correlated with whole-body glucose uptake. 41 In skeletal muscle, the data are less consistent. In non-diabetic Mexicans, lower ADIPOR1/2 mRNA levels in skeletal muscle have been observed in subjects with a family history of type 2 diabetes than in those with no family history of the disease, 42 but ADIPOR1/2 mRNA levels were similar in skeletal muscle of patients with type 2 diabetes and lean controls. 43 Furthermore, positive associations of ADIPOR1/2 mRNA levels with obesity, glucose and insulin levels and IR have been reported. 44 However, ADIPOR1 and ADIPOR2 mRNA levels in myotubes, cultured from metabolically characterized donors, did not correlate with indices of insulin sensitivity, but with insulin secretion and plasma triglycerides, respectively. 45 Hepatic expression of AdipoR1/2 in mice was inversely regulated by insulin. 20 The increased levels of hepatic ADIPOR1/R2 transcripts in insulin-resistant subjects are consistent with the animal data. Phosphorylation of Foxo1 by Akt/PKB, resulting in its nuclear exclusion, has been implicated in the insulin-dependent repression of several metabolic genes. 46, 47 Indeed, inhibitors of the PI3-kinase pathway as well as adenovirus-mediated gene transfer of constitutively active Foxo1 abrogated the inhibitory effect of insulin on AdipoR1/2 expression in C2C12 cells. 20 However, a subsequent study in the same cell line showed no effect of insulin on the expression of human ADIPOR2, while hormonal downregulation of ADIPOR1 was confirmed and characterized in detail. A putative insulin-responsive region composed of a nuclear inhibitory protein-binding element was identified that was required for insulin-dependent downregulation and FOXO1-mediated stimulation of ADIPOR1 transcription. 48 Importantly, no such element was identified in the ADIPOR2 promoter. Our own database search confirmed this difference between the ADIPOR1 and ADIPOR2 promoters. Hence, although we did not determine ADIPOR1 protein or FOXO1 phosporylation levels, the correlation of ADIPOR1 and FOXO1 mRNA in obese insulinresistant subjects as well as the activation of the ADIPOR1 promoter by FOXO1 is consistent with FOXO1-mediated upregulation of ADIPOR1 in IR. Conversely, the absence of a nuclear inhibitory protein-binding element in the ADIPOR2 promoter, the lack of its activation by FOXO1 in vitro as well as the absence of a correlation between ADIPOR2 and FOXO1 mRNA in vivo argue against a role of FOXO1 in the upregulation of ADIPOR2. Furthermore, distinct regulation of ADIPOR1/2 has been recently shown in that rosiglitazone enhanced transcription from the ADIPOR2, but not ADIPOR1 promoter in HepG2 cells through an interaction with a glucocorticoid receptor (GR) element. 49 In conclusion, our studies show enhanced hepatic ADIPOR1 and ADIPOR2 mRNA expression in insulin-resistant obese humans and suggest differential regulation of ADIPOR1/2 by FOXO1. Although mainly descriptive in nature, these data may add to previous knowledge obtained from studies in cell lines and animals and help to understand the regulation of adiponectin receptors in humans.
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